Additionally, PPARα plays a role in inhibiting hepatic inflammation, reducing liver fibrosis, and preventing hepatic steatosis, thereby mitigating the progression of MASLD and NASH (56). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.